The Central Government has notified two landmark amendments to India’s drug regulatory framework. The dual updates—notified by the Ministry of Chemicals and Fertilizers and the Ministry of Health and Family Welfare—modernize how essential medicine prices are controlled while formally bringing advanced biotherapies under federal drug laws. Together, they simultaneously address healthcare affordability and clinical innovation.
The core regulatory overhauls change compliance for drugmakers and access path for patients:
1. Revisions to the Drugs (Prices Control) Order (DPCO), 2013
The amendment to the DPCO alters how the National Pharmaceutical Pricing Authority (NPPA) fixes, implements, and enforces ceiling prices for essential medicines to enhance ease of doing business while protecting consumers:
- Flexible Packaging & Pack Size Pricing: Regulators can now notify separate ceiling or retail prices for the same drug based on its specific pack size, packaging type, content form (liquid vs. gaseous), or dosage compliance presentation.
- Restricted Overcharging Liability: Addressing a long-standing industry dispute, a manufacturer’s liability for overcharging will now be legally restricted to the specific quantity of stock found to be sold above the ceiling price by distributors or retailers, provided the manufacturer proves price revisions were properly communicated.
- Simplified Regulatory Filings: Companies launching an identical new drug within 12 months of its initial retail price fixation no longer need a separate NPPA approval. Instead, they can simply file a newly introduced Form IA within one month of launch. However, they are strictly barred from charging any amount higher than the prevailing capped retail price.
- Stricter Compliance and Record-Keeping: To ensure consumers benefit from downward price corrections, manufacturers must publicize price drops in at least two national newspapers, issue revised lists to dealers, and maintain a dedicated DPCO page on their websites. Furthermore, pharma companies are now legally mandated to preserve sales and production records for at least seven financial years.
2. Formal Inclusion of “Cell or Stem Cell” Derived Drugs
The second amendment expands the historical scope of the Drugs Rules, 1945. While the legacy framework explicitly mentioned only recombinant DNA-derived medications, the rapid rise of modern biotechnology left newer cell-based treatment models in a regulatory gray area.
The update formally incorporates advanced clinical protocols within the standard regulatory framework. Moving forward, a structured, legally clear approval, manufacturing, and import pathway applies to:
- Cell or Stem Cell-derived products
- Gene therapeutic products
- Xenografts (tissue grafts from another species)
Industry Reception
The pharmaceutical industry has widely praised the changes. Sudarshan Jain, Director General of the Indian Pharmaceutical Alliance, noted that the updates establish a critical “standardized approach to evaluation” across various Indian states. Industry bodies have added that the balanced updates provide much-needed regulatory clarity, promote ease of doing business, and reinforce stringent consumer protections.